Trial Profile
Phase I trial of oral WX 554 in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Nov 2017
Price :
$35
*
At a glance
- Drugs WX 554 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 18 Jan 2012 Results have been presented in a Wilex AG media release.
- 18 Jan 2012 Status changed from recruiting to completed, according to a Wilex media release.